Non-tech. summaries 2015: projects on oncology
Projects granted during 2015 that have a primary purpose of basic research: oncology.
Documents
Details
This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2015 with a primary purpose of basic research: oncology.
It contains a full list of the 41 projects that were granted.
The projects covered are:
-
analysing the genetic and epigenetic control of cancer (cancer, genetics, epigenetics)
-
helicobacter pylori virulence, immunity and disease (helicobacter pylori, virulence factors, carcinogenesis)
-
models of intestinal and genetically related tumours (colorectal tumours, cancer evolution, genetics)
-
radiation-induced leukaemogenesis (leukaemia, radio-sensitive, bone marrow)
-
investigation of tumourigenic pathways (tumour, oncogene, signalling)
-
new strategies for the diagnosis and treatment of glioma (brain tumour, glioma, diagnosis, treatment)
-
glioblastoma treatment and resistance (cancer, brain, rodent, treatment, resistance)
-
in vivo models of childhood leukaemia (childhood leukaemia, new therapies)
-
in vivo studies of tumour associated fibroblasts (fibroblast, cancer, mouse, genetically modified)
-
experimental cancer chemotherapy (xenograft chemotherapy non-genotoxic)
-
arginine methylation and tumourigenesis (cancer, genetically engineered mice)
-
epigenetics of cell senescence, cancer and ageing (epigenetics, cancer, ageing, mouse models)
-
analysis of stressors, nutrition and ageing in cancer (stress, cancer, treatment, ageing, diagnostics)
-
tumour progression in zebrafish models of cancer (cancer, cell signalling, biosensor, tumour microenvironment, optical projection tomography (OPT))
-
investigating human pancreatic cancer in mice (pancreatic cancer, genes, therapy)
-
analysing cancer metastasis and therapy failure (cancer, cell movement, imaging, metastasis, treatment)
-
elucidating novel actionable mutations in cancer (enzymes, genetics, cancer drivers, drug pathways, tumour-suppressing enzymes)
-
aspects of cancer regulation (cancer, macrophage, dormancy, lncRNAs)
-
cellular and molecular haematopoietic dynamics in health and disease (stem cells, haematopoiesis, transplantation, intravital microscopy, stem cell niche)
-
imaging of cell therapy in tumour models (tumour, cell therapy, imaging)
-
pancreatic cancer – improving our understanding and therapeutic options (pancreatic cancer, therapeutic, genotype/phenotype)
-
targeting the mechanisms of tumour vascularisation (cancer, metastasis, tumour stroma, angiogenesis, therapy)
-
defining mechanisms of cancer progression and dissemination (cancer, metastasis, microenvironment, imaging)
-
assessment of tumour initiation and metastatic spread (cancer, metastasis, drugs, endocrine resistance)
-
RUNX1 functions in normal tissues and cancers (haematopoiesis, leukaemia, cancer, reprogramming)
-
cytokine signalling in development and disease (TGF-13 superfamily signalling, transcription, cancer, embryonic development, signal transduction)
-
NKT cells and related immunity in health and disease (cancer obesity NKT (cells) immunotherapy)
-
signalling pathways in cancer (cancer, protein kinase, protein phosphatise)
-
mouse models of prostate cancer initiation and progression (cancer, prostate, tumour-initiating cells, metastasis, therapy)
-
characterisation of cellular heterogeneity in ovarian cancer (stem cells, xenotransplantation, cancer, lineage- tracing)
-
mouse models of KRAS-driven cancer progression & therapy (lung cancer, oncogene, metastasis, therapy)
-
inflammation and viral tumourigenesis (EBV, cancer, chronic inflammation, anti-oxidant)
-
mouse models of human cancer (cancer, GEMS, therapy, transplantation)
-
investigating epithelial cancer in vivo (colorectal cancer, pancreatic cancer, therapy)
-
cancer imaging and drug development (cancer, imaging, diagnosis, early response, drug development)
-
p53-family in physiology and cancer (cancer, aging, development, metabolism)
-
novel functions of p53 mutations in tumour progression (tumours, mutant p53, RCP, engulfment)
-
combining immunotherapy with current cancer treatments (cancer, oncolytic virus, magnetic particles, MRI, macrophages)
-
validation of tumour vascular targets and associated therapies (angiogenesis, cancer, vascular targets)
-
models advancing knowledge and treatment of paediatric brain cancer (paediatric, brain, cancer, treatment, biology)
-
evaluation of novel drug formulations in pancreatic cancer (cancer, drugs, nanotechnology, imaging, targeting)